Showing results (211-220 of 231) with videos related to
Sort By:
Pageof 24
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.The New England Journal of Medicine|December 8, 2025
Dual Targeting of Extramedullary Myeloma with Talquetamab and TeclistamabShaji Kumar, María-Victoria Mateos, Jing Christine Ye, et al.Transplantation and Cellular Therapy|March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple MyelomaBinod Dhakal, Nina Shah, Ankit Kansagra, et al.Journal of Hematology & Oncology|August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.Ejhaem|August 19, 2024
Variation in immunoglobulin use and impact on survival in myelomaKhai Li Chai, Cameron Wellard, Ltp Thao, et al.American Journal of Hematology|June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic riskShambavi Richard, Ajai Chari, Sosana Delimpasi, et al.The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.Journal of Hematology & Oncology|April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaMaria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.Pageof 24